Our study also suggests that administration of TGFβ antagonists during chemotherapy may sensitize carcinoma cells, in part through the inhibition of EMT, to the anti-tumor and anti-metastatic activities of chemotherapy resulting in increased therapeutic efficacy and reduced dosage of chemotherapeutics and their unwanted side effects. The gene discussed is TGFB1; the disease is carcinoma.